araag2/HINT huggingface dataset:
Clinical trial NCT00530764 (phase 2, status: completed)
Conditions: palliative care, pain, cancer
ICD codes: Z51.5, N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sativex low dose, sativex medium dose, sativex high dose
SMILES: [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1, [H][C@@]12C=C(C)CC[C@@]1([H])C(C)(C)OC1=C2C(O)=CC(CCCCC)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  The patient has advanced active cancer for which there is no known curative therapy.

          -  The patient is able (in the investigators opinion) and willing to comply with all
             study requirements.

          -  The patient has a clinical diagnosis of cancer related pain, which is not wholly
             alleviated with their current opioid treatment.

          -  The patient is receiving a sustained release (SR) fixed dose of opioid therapy
             (excluding Methadone). N.B. The opiate therapy must be Step III according to the World
             Health Organization (WHO) analgesic ladder.

          -  The patient is willing to continue to take their regular daily baseline opioid regimen
             (SR) at the same dose, throughout the duration of study.

        Exclusion Criteria:

          -  The patient should be excluded from entering study if they have received or are due to
             receive during the study period; chemotherapy, hormone therapy or radiotherapy, which,
             in the opinion of the investigator will affect their pain.

          -  Any history or immediate family history of schizophrenia, other psychotic illness,
             severe personality disorder or other significant psychiatric disorder other than
             depression associated with their underlying condition.

          -  Any known or suspected history of a diagnosed dependence disorder, current heavy
             alcohol consumption, current use of an illicit drug or current non prescribed use of
             any prescription drug.

          -  The patient has poorly controlled epilepsy or recurrent seizures (i.e. at least one
             year since last seizure).

          -  The patient has experienced myocardial infarction or clinically relevant cardiac
             dysfunction within the last 12 months or has a cardiac disorder that, in the opinion
             of the investigator would put the patient at risk of a clinically relevant arrhythmia
             or myocardial infarction.
Clinical trial NCT00356681 (phase 2, status: terminated)
Conditions: breast neoplasms, breast tumors, breast cancer, locally recurrent and metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: amg 706 placebo, bevacizumab, amg 706, paclitaxel
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    sponsor decision to close study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast with locally
             recurrent or metastatic disease.

          -  Measurable disease by RECIST guidelines.

          -  Tumor (primary or metastatic) must be HER2 negative.

          -  Adequate organ and hematologic function. Exclusion:

          -  Taxane treatment within 12 months prior to registration.

          -  Prior chemotherapy for locally recurrent or metastatic breast cancer (prior endocrine
             therapy is permitted).

          -  Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic
             chemoembolization on all sites of measurable disease.

          -  Current or prior history of central nervous system metastases.

          -  Peripheral neuropathy ≥ grade 2 (CTCAE v3.0) at registration.

          -  History of arterial or venous thrombosis within 1 year prior to registration.

          -  History of bleeding diathesis or bleeding within 14 days of registration.

          -  Uncontrolled hypertension (systolic >145 mmHg; diastolic >85 mmHg).

          -  Clinically significant cardiac disease within 12 months of registration.

          -  Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive.

          -  Prior treatment with VEGFr targeted therapies.
Clinical trial NCT00330187 (phase 2, status: completed)
Conditions: nicotine dependence, nicotine use disorder
ICD codes: F17.200, F17.210, F17.208, F17.209, F17.218, F17.219, F17.228, F17.208, F17.209, F17.218, F17.219, F17.228, F17.229, F17.298
Drugs: bupropion sr
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Regular cigarette smokers smoking at least 5 cigarettes per day as derived by
             Time-Line Follow-Back method (Sobell et al., 1988). Average number of cigarettes per
             day (over past 30 days) will be used. Five cigarettes per day may seem low, but based
             on previous studies, adolescents tend to smoke fewer cigarettes per day as compared to
             adults.

          2. Baseline urine cotinine level greater than 100 ng/ml.

          3. Age range of 12 - 21

          4. If under 18 yr. of age, parent(s) or guardian(s) able to participate in informed
             consent and initial assessment, or the participant must provide evidence of
             emancipated status.

          5. For post menarchal female participants: agree to use birth control to avoid pregnancy.

        Exclusion Criteria:

          1. Active substance abuse/dependence (other than nicotine) within 2 weeks prior to
             participating in the study

          2. Lifetime bipolar affective disorder (BPAD), psychosis, eating disorders. Bupropion may
             have adverse consequence on participants with these psychiatric diagnoses.

          3. Current major depressive disorders. Since bupropion is also an antidepressant, this
             criteria is to minimize the confound of depressive disorder during the study. History
             of depressive disorders and current attention deficit hyperactivity disorder (ADHD)
             will not be an exclusion. We will use permuted block randomization procedure to
             balance the groups for ADHD.

          4. Pregnancy or lactation. The safety of bupropion in pregnancy and during lactation is
             not well studied.

          5. History of seizure disorder or predisposition to seizures (e.g., history of
             significant head trauma, currently taking medications that lower seizure threshold),
             since bupropion can lower seizure threshold.

          6. History of severe renal, hepatic, neurological, or chronic pulmonary disease. This
             criterion was chosen due to the hepatic metabolism of bupropion.

          7. Unstable medical problems

          8. Allergy to bupropion

          9. Current treatment with any other medication containing bupropion

         10. Current treatment with any monoamine oxidase (MAO) inhibitors currently or within 2
             weeks of starting the study since there may be serious and severe medical interactions
             between MAO inhibitors and bupropion SR.

         11. Current treatment with nicotine replacement therapy (NRT)

         12. History of intolerance or non-response to bupropion SR.

         13. Current (past month) suicide ideation

         14. Suicide attempt (past year)
Clinical trial NCT00426816 (phase 2, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: sb-649868, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male

          -  18-64 years of age (inclusive),

          -  Diagnosis of primary insomnia who have had symptoms for at least three months.

        Exclusion Criteria:

          -  Any clinically significant unstable medical or surgical condition (treated or
             untreated).

          -  Any history of a clinically significant abnormality of the neurological system
             (including cognitive disorders or significant head injury) or any history of seizure
             (including febrile seizure).
Clinical trial NCT00104130 (phase 2, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: kos-862
SMILES: [H]\C(=C(\C)[C@]1([H])C\C([H])=C(C)/CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1
Eligibility criteria:

        Inclusion Criteria:

          -  At least 18 years of age.

          -  Metastatic disease.

          -  One previous treatment including docetaxel (Taxotere).

          -  At least 3 weeks since last surgery/radiation/chemotherapy

          -  ECOG Performance Status of 0, 1 or 2

        Exclusion Criteria:

          -  Active brain metastases
Clinical trial NCT01812642 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: jnj-37822681
SMILES: FC1=C(F)C=C(CN2CCC(CC2)NC2=CC=C(N=N2)C(F)(F)F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Have schizophrenia diagnosis by Diagnostic and Statistical Manual of Mental Disorders,
             fourth edition (DSM-IV)

          -  known history of schizophrenia of at least 12 months by the referring psychiatrist

          -  Positive and Negative Syndrome Scale score at Screening less than 70

          -  Body Mass Index (BMI) between 18 and 35 kilogram divided by square meter inclusive
             (BMI =weight per square height)

          -  Female participants must meet any one of the following: postmenopausal (amenorrhea for
             at least 12 months and Follicle Stimulating Hormone levels of greater than 40
             milli-international unit (MIU ) per milliliter at Screening), surgically sterile (have
             had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise be incapable
             of pregnancy)

        Exclusion Criteria:

          -  Any medical condition that could potentially alter the absorption, metabolism or
             excretion of the study medication, such as Crohn's (serious inflammation of any part
             of the gastrointestinal tract) disease, liver disease, or renal disease

          -  Relevant history of any significant and/or unstable cardiovascular, respiratory,
             neurologic (including seizures or significant cerebrovascular), renal, hepatic,
             endocrine or immunologic diseases

          -  History of neuroleptic malignant syndrome

          -  Female participants of childbearing potential

          -  Significant risk of suicidal or violent behavior
Clinical trial NCT00636610 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vismodegib 150 mg, placebo to vismodegib, bevacizumab, modified folfox, folfiri
SMILES: CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1, CS(=O)(=O)C1=CC(Cl)=C(C=C1)C(=O)NC1=CC=C(Cl)C(=C1)C1=CC=CC=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Histologically confirmed metastatic colorectal cancer (CRC)

          -  Representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained
             slides, with an associated pathology report, must be confirmed to be available and
             requested at any time prior to entry of study

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

          -  Adequate hematopoetic capacity

          -  Adequate hepatic function

          -  Adequate renal function

          -  Use of an effective method of barrier contraception (for women of childbearing
             potential)

          -  Signed informed consent

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic CRC or adjuvant chemotherapy for CRC within the
             prior 6 months

          -  Clinically suspected or confirmed CNS metastases or carcinomatous meningitis

          -  Major surgical procedure within 4 weeks prior to the first day of treatment in this
             study (Day 1)

          -  Pelvic radiation within 2 weeks prior to Day 1

          -  Wound dehiscence requiring intervention, gastrointestinal perforation, or bowel
             obstruction

          -  Pregnancy or lactation

          -  Uncontrolled medical illnesses including the following: Infection requiring
             intravenous (IV) antibiotics, congestive heart failure not controlled with medication,
             hypertension not controlled with medication

          -  Thromboembolic disease

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates use of an investigational drug or that might affect interpretation of
             the results of the study or render the patient at high risk from treatment
             complications
Clinical trial NCT00373529 (phase 2, status: completed)
Conditions: acute myelogenous leukemia, acute myeloid leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder [AHD])

          -  Age ≥ 60 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG
             performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype
             defined as any cytogenetic profile except the presence of any of the following:

               -  t(8;21)(q22;q22)

               -  inv(16)(p13;q22 or t(16;16)(p13;q22)

               -  t(15;17)(q22;q12) and variants.

          -  Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal
             (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x
             ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine > 1.0 mg/dL, then the
             estimated glomerular filtration rate (GFR) must be > 60 mL/min/1.73 m^2 as calculated
             by the Modification of Diet in Renal Disease (MDRD) equation

          -  Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left
             ventricular fractional shortening ≥ 22%

        Exclusion Criteria:

          -  Diagnosis of acute promyelocytic leukemia

          -  Prior treatment with clofarabine

          -  Prior treatment for AML or an antecedent hematologic disorder

          -  Prior hematopoietic stem cell transplant (HSCT)

          -  Prior radiation therapy to the pelvis

          -  Investigational agent received within 30 days prior to the first dose of study drug

          -  Ongoing uncontrolled systemic infection

          -  Diagnosis of another malignancy, unless the patient has been disease-free for at least
             5 years following the completion of curative intent therapy with the following
             exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or
             cervical intraepithelial neoplasia regardless of disease-free duration are eligible
             for this study if definitive treatment for the condition has been completed; Patients
             with organ-confined prostate cancer with no evidence of recurrent or progressive
             disease based on PSA value are eligible for this study if hormonal therapy has been
             initiated or a radical prostatectomy has been performed

          -  Clinical evidence of central nervous system (CNS) involvement

          -  Severe concurrent medical condition or psychiatric disorder that would preclude study
             participation

          -  Positive human immunodeficiency virus (HIV) test
Clinical trial NCT00336479 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: telaprevir, ribavirin, pegylated interferon alfa 2a
SMILES: [H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hepatitis C virus Genotype 1 with detectable plasma hepatitis C virus RNA

          -  Have been infected with hepatitis C virus for greater than (>) 6 months

          -  Seronegative for hepatitis B surface antigen and Human Immunodeficiency Virus 1 and 2

          -  Must agree to use 2 methods of contraception, including 1 barrier method, during and
             for 24 weeks after the completion of the study (unless the subject is a female of
             documented non-child-bearing potential)

          -  Female subjects must have a negative pregnancy test at all visits before the first
             dose

        Exclusion Criteria:

          -  Received any approved or investigational drug or drug regimen for the treatment of
             hepatitis C

          -  Any medical contraindications to Pegylated Interferon Alfa 2a or Ribavirin therapy

          -  Any other cause of significant liver disease in addition to hepatitis C; this may
             include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis,
             autoimmune hepatitis, hemochromatosis, Wilson's disease, Nonalcoholic Steatohepatitis
             or primary biliary cirrhosis

          -  Diagnosed or suspected hepatocellular carcinoma

          -  Histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a
             liver biopsy taken within 2 years before study start

          -  Alcohol abuse or excessive use in the last 12 months

          -  Participation in any investigational drug study within 90 days before drug
             administration or participation in more than 2 drug studies in the last 12 months
             (exclusive of the current study)
Clinical trial NCT00520806 (phase 2/phase 3, status: completed)
Conditions: heart failure, congestive
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: relaxin, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalized for acute heart failure

          -  Dyspnea at rest or with minimal exertion

          -  Pulmonary congestion

          -  Able to provide informed consent

          -  Systolic blood pressure > 125 mmHg

          -  Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2

        Exclusion Criteria:

          -  Use of other IV therapies for acute heart failure

          -  Fever or sepsis

          -  Recent major neurologic event

          -  Recent major surgery

          -  Recent acute coronary syndrome

          -  Other recent investigational drug use
Clinical trial NCT00540670 (phase 2, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: e5555 50 mg, e5555 100 mg, e5555 200 mg, placebo
SMILES: CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CCOC1=CC2=C(C(=N)N(CC(=O)C3=CC(=C(OC)C(=C3)N3CCOCC3)C(C)(C)C)C2)C(F)=C1OCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. 45 - 80 years old (at time of informed consent).

          2. Male or female (females of childbearing potential must use contraception).

          3. Confirmed coronary artery disease.

          4. All subjects must be receiving aspirin (75 - 325 mg).

        Exclusion Criteria:

          1. Unwilling or unable to provide informed consent.

          2. History of acquired or congenital bleeding disorder, coagulopathy, or platelet
             disorder.

          3. Recent trauma or major surgery.

          4. Evidence of active pathological bleeding or history of bleeding such as
             gastrointestinal or genitourinary, unless the cause has been definitely corrected.

          5. History of intracranial bleeding or history of hemorrhagic retinopathy.

          6. New York Heart Association class III or IV congestive heart failure.

          7. Pregnant or lactating women.
Clinical trial NCT01156792 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fp 100, gsk2190915 100, gsk2190915 300, montelukast, placebo, fp/sal 100/50
SMILES: CCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1, CCOC1=CC=C(C=N1)C1=CC=C(CN2C(CC(C)(C)C(O)=O)=C(SC(C)(C)C)C3=CC(OCC4=CC=C(C)C=N4)=CC=C23)C=C1, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age: 12 years of age or older

          -  Non-, former or current smokers with a documented smoking history of ≤ 10 pack years

          -  Asthma diagnosis as defined by the National Institutes of Health

          -  Best FEV1 of 50% to <80% of the predicted normal value

          -  Post-albuterol FEV1/FVC ratio of >0.70 at Visit 1/1a (between 5:00AM and 12:00 noon)

          -  ≥ 12% and ≥200mL reversibility of FEV1

          -  Must have been using FP 100mcg inhalation powder BID for at least 2 weeks just prior
             to Visit 1.

          -  Must be able to replace their current short-acting beta2-agonists with albuterol
             inhalation aerosol

          -  Must be able and willing to give written informed consent to take part in the study.

          -  Must be able and willing to comply with all aspects of the study including completion
             of daily e-Diary.

        Exclusion criteria:

          -  History of life-threatening asthma

          -  Recent asthma exacerbation

          -  Concurrent respiratory disease

          -  Recent respiratory infection

          -  Liver disease

          -  Other concurrent diseases/abnormalities

          -  Oral candidiasis

          -  Drug allergy

          -  Milk protein allergy

          -  Immunosuppressive Medications

          -  Administration of systemic, oral or depot corticosteroids within 12 weeks of Visit 1

          -  OATP1B1 substrates within 4 weeks of Visit 1

          -  Cytochrome P450 3A4 (CYP 3A4) Inhibitors

          -  Cytochrome P450 3A4 (CYP 3A4) Inducers

          -  Investigational Medications

          -  Compliance: any infirmity, disability, or geographical location which seems likely (in
             the opinion of the Investigator) to impair compliance with any aspect of this study
             protocol

          -  Affiliation with Investigator's Site